Yoshinami Yuri, Shoji Hirokazu
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Future Sci OA. 2023 Mar 17;9(2):FSO842. doi: 10.2144/fsoa-2023-0002. eCollection 2023 Feb.
Our increasing understanding of the molecular biological characteristics of cancer and of cancer genomics is facilitating the development of immunotherapy and molecular targeted drugs for gastric cancer. After the approval of immune checkpoint inhibitors (ICIs) for melanoma in 2010, many different cancers have been shown to respond to such treatments. Thus, the anti-PD-1 antibody nivolumab was reported to prolong survival in 2017, and ICIs have become the mainstay of treatment development. Many clinical trials of combination therapies with cytotoxic agents and molecular-targeted agents, as well as combinations of immunotherapeutic agents acting via different mechanisms, are currently underway for each treatment line. As a result, further improvements in therapeutic outcomes for gastric cancer are anticipated in the near future.
我们对癌症分子生物学特征和癌症基因组学的认识不断加深，这推动了胃癌免疫疗法和分子靶向药物的发展。2010年免疫检查点抑制剂（ICI）获批用于治疗黑色素瘤后，许多不同类型的癌症已被证明对此类治疗有反应。因此，2017年有报道称抗PD-1抗体纳武单抗可延长生存期，ICI已成为治疗发展的主流。目前，针对每个治疗线，都在进行许多将细胞毒性药物和分子靶向药物联合使用的临床试验，以及通过不同机制起作用的免疫治疗药物联合使用的试验。因此，预计在不久的将来，胃癌的治疗效果将得到进一步改善。
